Leendert A Trouw

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Leendert A Trouw. Retrieved from https://idiyas.com/inventor/leendert-a-trouw-yzwfv1nw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
 

Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Leendert A Trouw: Innovator in Molecular Biology

Introduction

Leendert A Trouw is a notable inventor in the field of molecular biology. He has made significant contributions to the diagnosis of rheumatoid arthritis through his innovative methods. His work focuses on the detection of anti-carbamylated protein (anti-CarP) antibodies in the serum of patients suffering from this condition.

Latest Patents

Leendert A Trouw holds a patent titled "Compositions And Methods For The Diagnosis Of Rheumatoid Arthritis." This patent outlines methods for identifying specific antibodies that are crucial for diagnosing rheumatoid arthritis, showcasing his expertise in the field.

Career Highlights

Throughout his career, Leendert has worked with prominent organizations such as Inova Diagnostics, Inc. and Leiden University Medical Center. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Leendert has collaborated with various professionals in his field, including Michael Mahler. These partnerships have enhanced his research and broadened the impact of his work.

Conclusion

Leendert A Trouw is a distinguished inventor whose work in molecular biology has paved the way for advancements in the diagnosis of rheumatoid arthritis. His contributions continue to influence the field and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…